Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 29479A108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
City Hill, LLC
13G/A
|
10.4% |
8/14/2026
Event 6/30/2026
|
||
| City Hill, LLC | 3.7% | |||
| Jonathan E. Lim | 10.4% | |||
| Conyee T. Lim | 5.6% | |||
| T. Rowe Price Investment Management, Inc. 13G/A | 6.8% |
5/15/2026
Event 3/31/2026
|
||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
5.3% |
5/15/2026
Event 3/31/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 5.3% | |||
| VHCP Co-Investment Holdings III, LLC | 5.3% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 5.3% | |||
| VHCP Management III, LLC | 5.3% | |||
| VHCP Management EG, LLC | 5.3% | |||
| Nimish Shah | 5.3% | |||
| Bong Y. Koh | 5.3% | |||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
5.3% |
8/14/2025
Event 6/30/2025
|
||
| Frazier Life Sciences Public Fund, L.P. | 5.3% | |||
| FHMLSP, L.P. | 5.3% | |||
| FHMLSP, L.L.C. | 5.3% | |||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.8% | |||
| FHMLSP Overage, L.P. | 0.8% | |||
| FHMLSP Overage, L.L.C. | 0.8% | |||
| Frazier Life Sciences X, L.P. | 0.6% | |||
| FHMLS X, L.P. | 0.6% | |||
| FHMLS X, L.L.C. | 0.6% | |||
| Frazier Life Sciences XI, L.P. | 1.3% | |||
| FHMLS XI, L.P. | 1.3% | |||
| FHMLS XI, L.L.C. | 1.3% | |||
| James N. Topper | 0.6% | |||
| Patrick J. Heron | 0.6% | |||
| Albert Cha | 0% | |||
| James Brush | 0% | |||
| Daniel Estes | 0% | |||
|
RTW Investments, LP
13G
|
5.2% |
5/15/2026
Event 3/31/2026
|
||
| RTW Investments, LP | 5.2% | |||
| Roderick Wong | 5.2% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
Logos Global Management LP
13G/A
|
4.8% |
11/14/2025
Event 9/30/2025
|
||
| Logos Global Management LP | 4.8% | |||
| Logos Global Management GP LLC | 4.8% | |||
| Arsani William | 4.8% | |||
|
Novartis Pharma AG
13G/A
|
4.4% |
2/12/2025
Event 12/31/2024
|
||
| Novartis Pharma AG | 4.4% | |||
| Novartis AG | 4.4% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
3.3% |
5/15/2026
Event 3/31/2026
|
||
| Paradigm BioCapital Advisors LP | 3.3% | |||
| Paradigm BioCapital Advisors GP LLC | 3.3% | |||
| Senai Asefaw, M.D. | 3.3% | |||
| Paradigm BioCapital International Fund Ltd. | 2.9% | |||
|
Suvretta Capital Management, LLC
13G/A
|
1.1% |
5/12/2026
Event 3/31/2026
|
||
| Suvretta Capital Management, LLC | 1.1% | |||
| Averill Master Fund, Ltd. | 0.9% | |||
| Aaron Cowen | 1.1% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 5.33 k | $78.1 k |
| 2026 Q2 | 274 | 284 M | $5.32 B |
| 2026 Q1 | 236 | 274 M | $4.39 B |
| 2025 Q4 | 161 | 224 M | $834 M |
| 2025 Q3 | 147 | 216 M | $471 M |
| 2025 Q2 | 146 | 219 M | $278 M |
| 2025 Q1 | 158 | 224 M | $307 M |
| 2024 Q4 | 152 | 231 M | $580 M |
| 2024 Q3 | 138 | 234 M | $639 M |
| 2024 Q2 | 133 | 213 M | $503 M |
| 2024 Q1 | 117 | 74.1 M | $153 M |
| 2023 Q4 | 125 | 71.3 M | $152 M |
| 2023 Q3 | 114 | 71.3 M | $140 M |
| 2023 Q2 | 115 | 74.3 M | $205 M |
| 2023 Q1 | 122 | 78.0 M | $235 M |
| 2022 Q4 | 114 | 83.7 M | $361 M |
| 2022 Q3 | 91 | 80.5 M | $628 M |
| 2022 Q2 | 90 | 76.9 M | $428 M |
| 2022 Q1 | 84 | 72.9 M | $627 M |
| 2021 Q4 | 64 | 63.7 M | $988 M |
| 2021 Q3 | 56 | 44.2 M | $920 M |